Insider · CIK 0001678736
Konstantin Poukalov
Files at LYRA (Lyra Therapeutics, Inc.), LIANY (LianBio), ARYD (ARYA Sciences Acquisition Corp IV). First filing -, latest -.
In brief
Konstantin Poukalov files SEC Form 4 as director and officer at LYRA (Lyra Therapeutics, Inc.), and also at LIANY (LianBio), ARYD (ARYA Sciences Acquisition Corp IV). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Konstantin Poukalov has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 13, 2024 | LYRA Lyra Therapeutics, Inc. | AGrant or award Stock Optionderivative | +30,000 | $0.00 | $0 | 30,000 | Jun 14, 2024 |
| Feb 15, 2024 | LIANY LianBio | MOption exercise Ordinary Shares | +36,300 | $2.52 | $91k | 36,300 | Feb 20, 2024 |
| Feb 15, 2024 | LIANY LianBio | FTax withholding Ordinary Shares | -19,218 | $4.76 | $91k | 17,082 | Feb 20, 2024 |
| Feb 15, 2024 | LIANY LianBio | MOption exercise Stock Option (Right to Buy)derivative | -36,300 | $0.00 | $0 | 0 | Feb 20, 2024 |
Questions about Konstantin Poukalov
Answered from the filings on this page, as of the latest one.
Is Konstantin Poukalov buying or selling?
Konstantin Poukalov has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Konstantin Poukalov's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Konstantin Poukalov has 0.
Where does Konstantin Poukalov file Form 4?
Konstantin Poukalov has filed Form 4 at LYRA (Lyra Therapeutics, Inc.); LIANY (LianBio); ARYD (ARYA Sciences Acquisition Corp IV) as Chief Business Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.